BACKGROUND: The management of critically ill hyperglycemic patients in the intensive care unit (ICU) has been fraught with recent controversy. Only one randomized trial has demonstrated a mortality benefit to intensive glycemic control, with all subsequent studies failing to confirm this benefit and revealing a markedly increased risk of severe hypoglycemia (SH) in intensively treated patients. In most of these trials, adherence to the protocols were neither tracked nor reported. METHODS: A retrospective analysis of all patients admitted to an ICU who were treated with an insulin infusion directed by the GlucoCare™ IGC System, an FDA-cleared insulin-dosing calculator (Yale 100-140 mg/dL protocol). Mean blood glucose (BG) levels, time to target range and incidence of SH (<40 mg/dL) and moderate hypoglycemia (MH) (40-69 mg/dL) were determined, and potential causes of hypoglycemic episodes were assessed. RESULTS: Mean post-target BG was approximately 123 mg/dL. Of >55,000 readings in 1,657 patients, overall incidence of SH was 0.01% of readings and 0.3% of patients. MH occurred in 1.1% of readings and 17.6% of patients. The top potential causes of MH were: (1) Protocol-directed recommendations including continuation of insulin with BG <100 mg/dL and decreases in the frequency of BG checks (63.7%), and (2) Staff non-adherence to protocol directives (15.3%). CONCLUSIONS: The results of the GlucoCare-directed Yale 100-140 mg/dL protocol experience revealed an extremely low incidence of SH and an incidence of MH of 1.1%. The incidence of SH in this study was lower than the control group of the NICE-SUGAR study and are supportive of the new Society of Critical Care guidelines to target BG levels of 100-150 mg/dL in critically ill patients. Further refinements to the original protocol and emphasis on staff adherence to protocol directives could potentially further reduce these very low hypoglycemia rates.
BACKGROUND: The management of critically ill hyperglycemicpatients in the intensive care unit (ICU) has been fraught with recent controversy. Only one randomized trial has demonstrated a mortality benefit to intensive glycemic control, with all subsequent studies failing to confirm this benefit and revealing a markedly increased risk of severe hypoglycemia (SH) in intensively treated patients. In most of these trials, adherence to the protocols were neither tracked nor reported. METHODS: A retrospective analysis of all patients admitted to an ICU who were treated with an insulin infusion directed by the GlucoCare™ IGC System, an FDA-cleared insulin-dosing calculator (Yale 100-140 mg/dL protocol). Mean blood glucose (BG) levels, time to target range and incidence of SH (<40 mg/dL) and moderate hypoglycemia (MH) (40-69 mg/dL) were determined, and potential causes of hypoglycemic episodes were assessed. RESULTS: Mean post-target BG was approximately 123 mg/dL. Of >55,000 readings in 1,657 patients, overall incidence of SH was 0.01% of readings and 0.3% of patients. MH occurred in 1.1% of readings and 17.6% of patients. The top potential causes of MH were: (1) Protocol-directed recommendations including continuation of insulin with BG <100 mg/dL and decreases in the frequency of BG checks (63.7%), and (2) Staff non-adherence to protocol directives (15.3%). CONCLUSIONS: The results of the GlucoCare-directed Yale 100-140 mg/dL protocol experience revealed an extremely low incidence of SH and an incidence of MH of 1.1%. The incidence of SH in this study was lower than the control group of the NICE-SUGAR study and are supportive of the new Society of Critical Care guidelines to target BG levels of 100-150 mg/dL in critically illpatients. Further refinements to the original protocol and emphasis on staff adherence to protocol directives could potentially further reduce these very low hypoglycemia rates.
Authors: Etie S Moghissi; Mary T Korytkowski; Monica DiNardo; Daniel Einhorn; Richard Hellman; Irl B Hirsch; Silvio E Inzucchi; Faramarz Ismail-Beigi; M Sue Kirkman; Guillermo E Umpierrez Journal: Endocr Pract Date: 2009 May-Jun Impact factor: 3.443
Authors: Judith Jacobi; Nicholas Bircher; James Krinsley; Michael Agus; Susan S Braithwaite; Clifford Deutschman; Amado X Freire; Douglas Geehan; Benjamin Kohl; Stanley A Nasraway; Mark Rigby; Karen Sands; Lynn Schallom; Beth Taylor; Guillermo Umpierrez; John Mazuski; Holger Schunemann Journal: Crit Care Med Date: 2012-12 Impact factor: 7.598
Authors: Gunjan Y Gandhi; Gregory A Nuttall; Martin D Abel; Charles J Mullany; Hartzell V Schaff; Peter C O'Brien; Matthew G Johnson; Arthur R Williams; Susanne M Cutshall; Lisa M Mundy; Robert A Rizza; M Molly McMahon Journal: Ann Intern Med Date: 2007-02-20 Impact factor: 25.391
Authors: Christopher A Newton; Dawn Smiley; Bruce W Bode; Abbas E Kitabchi; Paul C Davidson; Sol Jacobs; R Dennis Steed; Frankie Stentz; Limin Peng; Patrick Mulligan; Amado X Freire; Angel Temponi; Guillermo E Umpierrez Journal: J Hosp Med Date: 2010-10 Impact factor: 2.960
Authors: Philip A Goldberg; Mark D Siegel; Robert S Sherwin; Joshua I Halickman; Michelle Lee; Valerie A Bailey; Sandy L Lee; James D Dziura; Silvio E Inzucchi Journal: Diabetes Care Date: 2004-02 Impact factor: 19.112
Authors: Frank M Brunkhorst; Christoph Engel; Frank Bloos; Andreas Meier-Hellmann; Max Ragaller; Norbert Weiler; Onnen Moerer; Matthias Gruendling; Michael Oppert; Stefan Grond; Derk Olthoff; Ulrich Jaschinski; Stefan John; Rolf Rossaint; Tobias Welte; Martin Schaefer; Peter Kern; Evelyn Kuhnt; Michael Kiehntopf; Christiane Hartog; Charles Natanson; Markus Loeffler; Konrad Reinhart Journal: N Engl J Med Date: 2008-01-10 Impact factor: 91.245
Authors: Mathijs Vogelzang; Bert G Loef; Joost G Regtien; Iwan C C van der Horst; Hein van Assen; Felix Zijlstra; Maarten W N Nijsten Journal: Intensive Care Med Date: 2008-04-04 Impact factor: 17.440
Authors: Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuk Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger Journal: Intensive Care Med Date: 2017-01-18 Impact factor: 17.440
Authors: Daniel Shelden; Mohammed Ateya; Angela Jensen; Patrick Arnold; Tiffany Bellomo; Roma Gianchandani Journal: J Diabetes Sci Technol Date: 2020-12-23